Innovating.works Conecta tu I+D

Mostrando 1 al 20 de 45 resultados

REALMENT: Using real world big data from eHealth biobanks and national registries integrated with clinical t... ISLENSK ERFDAGREINING EHF participó en un H2020: H2020-SC1-BHC-2018-2020 Mental disorders represent one of the largest burdens for the European Health Care system, due to large number of patients and a lack of eff...
2021-01-29 - 2025-11-30 | Financiado

PainFACT: Molecular Mechanisms Associating Chronic Pain with Fatigue Affective Disorders Cardiovascular Dise... Chronic pain (CP) is the leading cause of disability, and is strongly associated with fatigue, anxiety and depression ─ also major contribut...
2019-11-22 - 2025-12-31 | Financiado

CoMorMent: Predicting comorbid cardiovascular disease in individuals with mental disorder by decoding disease m... ISLENSK ERFDAGREINING EHF participó en un H2020: H2020-SC1-BHC-2018-2020 Comorbid cardiovascular disease in people with severe mental disorders is a major public health concern and poses a considerable financial b...
2019-11-21 - 2024-12-31 | Financiado

ImPRESS: International Interdisciplinary PhD studies in Biomedical Research and Biostatistics. Supporting the... ISLENSK ERFDAGREINING EHF participó en un H2020: H2020-MSCA-COFUND-2016 The aim of the project is to launch Interdisciplinary PhD Studies in Biomedicine aimed at young aspiring scientists, who will conduct resear...
2017-05-12 - 2023-01-31 | Financiado

STEMBANCC: Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC) ISLENSK ERFDAGREINING EHF participó en un FP6: StemBANCC, comprising internationally renowned investigators, is ideally positioned to deliver a unique European biorepository and drug disc...
2012-10-01 - 2018-03-31 | Financiado

EU-AIMS: European Autism Interventions - A Multicentre Study for Developing New Medications ISLENSK ERFDAGREINING EHF participó en un FP6: Despite dramatic advances in molecular and imaging technologies, there are currently no effective pharmacological treatments for the core sy...
2012-04-01 - 2018-03-31 | Financiado

BIOVACSAFE: Biomarkers For Enhanced Vaccine Safety ISLENSK ERFDAGREINING EHF participó en un FP6: BioVacSafe is a concise consortium of selected academic, public, and SME participants used to co-working in industry-led projects, organised...
2012-03-01 - 2018-08-31 | Financiado

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia ISLENSK ERFDAGREINING EHF participó en un FP6: Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are...
2009-09-01 - 2015-02-28 | Financiado

PSYCHCNVS: Copy number variations conferring risk of psychiatric disorders in children ISLENSK ERFDAGREINING EHF tramitó un FP7: The recent technical improvements for the study of the cytogenetic basis of disease have led to the identification of many microdeletion and...
Financiado

PSYCHDPC: Psychiatric Diagnostic and Prevention Consortium ISLENSK ERFDAGREINING EHF tramitó un FP7: PsychDPC contains leading European centres in genetics and psychiatry, richly endowed with expertise in both clinical and basic research. Th...
Financiado

PROMARK: Genetic prostate cancer variants as biomarkers of disease progression ISLENSK ERFDAGREINING EHF tramitó un FP7: Prostate cancer is the most common cancer in males in Europe, causing over 87,000 deaths in 2006. Early diagnosis and treatment are key fact...
Financiado

PSYCHGENE: Copy Number Variation and Endophenotypes in Psychiatric Disorders ISLENSK ERFDAGREINING EHF tramitó un FP7: A genome-wide copy number variant (CNV) association study for schizophrenia (SZ), bipolar disorder (BP) and major depression (MD) will be co...
Financiado

CANCERGENE: Identification and functional characterization of genetic cancer risk variants ISLENSK ERFDAGREINING EHF tramitó un FP7: This Industry-Academia Partnership and Pathways (IAPP) joins three groups which have hitherto focused on different aspects of cancer genetic...
Financiado

NEWMEDS: Novel Methods leading to New Medications in Depression and Schizophrenia ISLENSK ERFDAGREINING EHF participó en un FP7: Despite dramatic advances in molecular and imaging technologies and nearly 1 5,000 articles on schizophrenia and depression (S&D) there are...
Financiado

BBMRI-LPC: BBMRI Large Prospective Cohorts ISLENSK ERFDAGREINING EHF participó en un FP7: In recent years, biomedical research has crossed international borders in large, collaborative studies showing the value of multidisciplinar...
Financiado

ENGAGE: European Network for Genetic and Genomic Epidemiology ISLENSK ERFDAGREINING EHF participó en un FP7: ENGAGE (European Network for Genetic and Genomic Epidemiology) has, as its central objective, the translation of the wealth of data emerging...
Financiado

INTERPREGGEN: Genetic studies of pre eclampsia in Central Asian and European populations ISLENSK ERFDAGREINING EHF participó en un FP7: Pre-eclampsia, one of the most dangerous cardiometabolic complications of pregnancy, claims the lives of 50,000 mothers and almost one milli...
Financiado

GEN2PHEN: Genotype To Phenotype Databases A Holistic Solution ISLENSK ERFDAGREINING EHF participó en un FP7: The GEN2PHEN project aims to unify human and model organism genetic variation databases towards increasingly holistic views into Genotype-To...
Financiado

DECODE GENETICS EHF